The biofilm formation and antibiotic resistance of bacterial profile from endotracheal tube of patients admitted to intensive care unit in southwest of Iran

Zahra Dargahi1,2, Anas Abdullah Hamad3*, Ahmad Farajzade Sheikh2,4, Nazanin Ahmad Khosravi1,2, Shahla Samei Fard2, Moloudsadat Motahar1,2, Fatemeh Jahangiri Mehr6, Fariba Abbasif, Hossein Meghdadi1,2, Pejman Bakhtiyarinya2,4, Reza Heydari1,2, Melika Moradi2, Aram Asareh Zadegan Dezfuli1,2,4*

1 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, 2 Department of Microbiology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, 3 Department of Medical Laboratory Techniques, Al Maarif University College, Al Anbar, Ramadi, Iraq, 4 Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, 5 Pain Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, 6 Department of Microbiology, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

* anas.abdullah@uoa.edu.irq (AAH); aramasareth836@yahoo.com (AAZD)

Abstract

Ventilator-associated pneumonia (VAP) is a prevalent nosocomial illness in mechanically ventilated patients. Hence, the aim of this study was to investigate the pattern of antibiotic resistance and biofilm formation of bacterial profiles from Endotracheal Tubes of patients hospitalized in an intensive care unit in southwest Iran. According to the standard operating method, the microbiological laboratory conducts bacteria culture and susceptibility testing on endotracheal Tube samples suspected of carrying a bacterial infection. The Clinical and laboratory standards institute (CLSI) techniques are used to determine the Antimicrobial resistance (AMR) of bacterial isolates to antibiotics using the disk diffusion method. The crystal violet staining method was used to assess the biofilm-forming potential of isolates in a 96-well microtiter plate. In total, (51%) GPBs were included in this study. The isolated GPB were coagulase-negative Staphylococcus (16%), S. aureus (14%). In total, (40%) of GNB were included in this study. The isolated GNB were Klebsiella spp. (36%), A. baumanii (22%), P. aeruginosa (35%). (32%) bacterial strains were MDR and (29%) strains were XDR. The results of biofilm formation showed (72%) were biofilm producers. VAP is a common and severe nosocomial infection in mechanically ventilated patients. Controlling biofilm formation, whether on the ET or in the oropharyngeal cavity, is thus an important technique for treating VAP. Colistin and linezolid are antibiotics that are effective against practically all resistant GNB and GPB isolates.
Introduction

Ventilator-associated pneumonia (VAP) is known as a prevalent and deadly nosocomial infection in mechanically ventilated patients, mostly resulting in high mortality, and also long-term intensive care unit (ICU), longer duration of hospitalization, and increased cost. Over the last decades, the role of the endotracheal tube (ET) in VAP pathogenesis and also medical device-related infections has become prominent [1]. VAP is pneumonia that develops within 48–72 after endotracheal intubation and mechanical ventilation. Patients who suffer from this infection may present with a new or continuous infiltrate on chest radiography, together with fever, increased leukocyte count, and alterations in sputum features. Early VAP happens within the first 2–4 days of ventilation and is often caused by bacteria that are sensitive to antibiotics. Early VAP, on the other hand, occurs after 4 days and appears to be produced by multidrug-resistant bacteria [2]. Due to the presence of various infections caused by hospital pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, or methicillin-resistant Staphylococcus aureus (MRSA), the recognition of VAP from other infections is of high priority. Coagulase-negative staphylococci (CoNS) has been indicated to be resistant to some or all antibiotics, and the resultant infections mostly result in mortality in 13–25.5% of patients [3–5]. It is notable that in the ICU, 50% of the antibiotics recommended are for VAP management [6]. In the absence of a standard approach for VAP management, it is estimated that by 2050, approximately 10 million people will die each year as a result of resistance to antibiotics [7].

In intubated patients, the biofilm formation on ET is an early and constant process, and ET behaves as a reservoir to infect microorganisms. Immediately after intubation, a mixed biofilm, with the ability to harbor microbial pathogens, is formed on the ET. Microorganisms can exist as individual cells in a liquid medium or as an immobile community in biofilms [8]. A microbial biofilm is a three-dimensional collection of microbial cells enclosed in a self-produced matrix that protects it from the harsh environment. The matrix-enclosed communities of bacteria stick to each other and are adherent to inert or living surfaces; as a result, in these protected populations, the hosted microorganisms are able to survive in a dormant state. These persister cells, which seem to be metabolically inactive, make up a minor portion of the biofilm and remain in an immobile condition due to a slowed metabolism because they’re less vulnerable to the effects of antimicrobials [9].

A growing body of research shows that the incidence of antibiotic resistance varies geographically because there is some resistance to next-generation antibiotics. Such resistance appears to be an alarm, encouraging physicians to periodically examine the antibiotic resistance patterns and exploit these models for experimental and special treatment of infections [10–13]. Thus, each region needs to check dynamically and sustainably the patterns of its resistance and sensitivity so that the outcomes are applied as a guide for the appropriate administration of antibiotics in the aforesaid region. This action is of paramount importance in the ICU [14]. As a consequence, this study was carried out to assess the biofilm formation and antibiotic resistance of bacterial profile from Endotracheal Tube of patients admitted to Intensive care unit in the southwest Iran.

Inclusion criteria

The inclusion criteria were over 18 years of age and at least 5-day survival after intubation. Patient information, including gender, age, positive culture of tracheal secretions, type of cultured microorganism, sensitivity, and resistance to tested antibiotics was recorded for each patient.
Methods

Study design

This cross-sectional study was conducted from June 2020 to June 2021. The investigation included all clinical samples sent to the Golestan Hospital microbiology laboratory in Ahvaz, Iran. The hospital serves as a referral center for the public hospital in Ahvaz city.

Sample techniques and collection

The microbiological lab performed for bacteria were culture and sensitivity tests on the endotracheal Tube samples suspected of any bacterial infection based on the standard operating procedure. Specimens were obtained from ICU patients with a tracheal tube with endotracheal aspiration, when they had a clinical manifestation of pneumonia (cough, purulent respiratory secretion, fever & new or progressive infiltration of the lung in CXR) and were referred to the laboratory in the special sterile bottles (Lukens trap).

Microbial identification

All samples are cultured on an appropriate culture media—i.e. blood culture is conducted whenever a blood-stream infection is expected, in tryptase soy broth prepared in the laboratory. If there is an indication of growth like hemolysis, gas, and turbidity, the inoculum would be subcultured on an appropriate solid medium for further identification. Non-fastidious bacteria would be cultivated on Blood and MacConkey agar, whereas fastidious bacteria would be grown on Chocolate agar. The single bacterial colony from culture media would be taken for Gram staining. For preliminary identification of the bacteria, Gram staining and colony features are used. Gram-positive bacteria (GPB) would be cultured in blood agar, and mannitol salt agar. for suspected enterococcal colonies, we used a bile esculin test identified using catalase, coagulase, bacitracin, pyrrolidinyl acrylamides (PYRase), optochin bile solubility, and Novobiocin. Gram-negative bacteria (GNB) would be cultured in MacConkey agar and Eosin methylene blue agar. Then identified based on serial biochemical reactions and fermentation of carbohydrates i.e. oxidase, catalase, triple sugar iron agar, citrate utilization test, urease, lysine iron agar, Sulphur indole motility, and indole test. Standard strains were used for all tests and suspicious tests were checked twice [15].

Antibiotic resistance AMR profiles

The AMR of bacterial isolates to antibiotics is evaluated using the disk diffusion method in accordance with CLSI standards (2022). The isolates are classified as sensitive and resistant based on the diameter of the clearing zone according to CLSI (2022) guidelines. The antibiotic discs represented: ciprofloxacin (Fluorinated quinolones), clindamycin (Lincosamides), gentamycin (Aminoglycosides), erythromycin (Macrolides), sulphmethoxazole/trimethoprim (Sulphonamides), tetracycline (Tetracyclines), vancomycin (Glycopeptides), Quinupristin-dalfopristin (streptogramins), cefoxitin (penicillinase-stable penicillins), nitrofurantoin (nitrofurantoin), rifampin (ansamycins), and linezolid (oxazolidinones).

For antimicrobial drug susceptibility assay in Gram-negative anaerobic bacteria isolated from these infections, the Minimum Inhibitory Concentration (MIC) of imipenem, chloramphenicol, metronidazole, clindamycin, cefoxitin, and penicillin G (Sigma Chemical Co. USA) was determined by the agar dilution method. MIC of penicillin, metronidazole, clindamycin, and cefoxitin for Gram-positive anaerobic bacteria were determined by Etest strip (AB biomerieux, Sweden) according to CLSI guidelines for anaerobic susceptibility testing. The phenotype is defined as multiple drug resistance (MDR), extremely drug-resistant (XDR), and
pan-drug-resistant (PDR) according to the International Expert proposal for Interim Standards Guidelines [16, 17].

**Biofilm formation**

The crystal violet staining method was used to assess the biofilm forming potential of isolates in a 96-well microtiter plate. First, these isolates were inoculated in Mueller–Hinton agar at 37°C overnight. Then, these isolates were adjusted to 0.5 McFarland (~1.5x10⁸ CFU/mL) with normal saline (0.85% NaCl). A 10-μL aliquot of each suspension was then diluted 1:200 in 190 μL of tryptic soy broth (TSB) containing 1% glucose in 96-well polystyrene microtiter plates. Following incubation at 37°C overnight, the plates were washed three times with PBS, fixed by adding 200 μL of methanol into each well, and stained with 200 μL of 0.1% crystal violet (CV) for 20 minutes. The plates were rinsed three times further to eliminate excess stain, and the residual CV was solubilized by incubating in 200 L of 95% ethanol for 10 minutes. The optical density at 570 nm (OD570) of each well was measured by the ELISA plate reader (μQuant; BioTek Instruments, Winooski, VT, USA), to evaluate the biofilm formation capacity. _S. epidermidis_ ATCC 35984 and TSB broth were used as positive and negative controls (ODc) for the biofilm formation, respectively. The results were interpreted according to the criteria suggested by Zhang et al. Briefly, the isolates were classified into the several groups about the biofilm formation capacity: OD570 ≤ ODc = no biofilm producer; ODc < OD570 ≤ 2 × ODc = weak biofilm producer; 2 × ODc < OD570 ≤ 4 × ODc = moderate biofilm producer; and 4 × ODc < OD570 = strong biofilm producer [18]. All experiments were performed in triplicate.

**Ethics statement**

This study was approved by the Research Ethics Committee (REC) of the Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1399.38). Informed written consent was obtained from the patients or their relatives (for patients under the age of 18 years).

**Results**

**Dissemination of positive cultures/specimens**

During the period of study, 1139 bacterial positive growth samples were collected from patients. Most of the isolates were obtained from female patients and were detected in adults in the age range of 18–24 years (n = 470; 41%), followed by the age group of 24–64 years (n = 471; 41%). Duration of being intubated was evaluated; it was shown that duration of being intubated had a median of 9 days (Between 2 to 60 days). We were only focused in this investigation if there was an underlying illness. Underlying diseases are some diseases such as DM (diabetes mellitus), HTN (hypertension), hyperlipidemia, cardiovascular diseases, pulmonary diseases, and renal diseases. Patients over the age of 64 were found to have the fewest isolates. _Table 1_ shows the age and gender distribution of patients with bacterial isolates.

| Age group (y) | Total | Male | Female |
|---------------|-------|------|--------|
| Sex           | N (%) | N (%)| N (%)  |
| 18–24         | 318 (27%) | 102 (32%) | 368 (44%) | 470 (41%) |
| 24–64         | 818 (72%) | 121 (38%) | 350 (55%) | 471 (41%) |
| > 64          | 1136 (100) | 95 (29%) | 100 (12%) | 195 (17%) |

https://doi.org/10.1371/journal.pone.0277329.t001
Number of Gram positive of bacterial (GPB) and (GBN) isolates from endotracheal tube cultures of patients

In total, 593 GPBs (51%) were included in this study. The isolated GPB were coagulase-negative Staphylococcus (CoNS; n = 100/590; 16%), *S. aureus* (n = 119/590; 14%), *Enterococcus* spp. (n = 32/590; 0.05%), *Streptococcus* spp. (n = 277/590; 46%) and *Corynebacterium* spp. (n = 62/590; 10%) (Table 2). This study includes a total of 546 GNB (40%) were included in this study. The isolated GNB were *Klebsiella* spp. (n = 197/546; 36%), *A. baumannii* (n = 121/546; 22%), *P. aeruginosa* (n = 195/546; 35%) and *Neisseria gonorrhoeae* (n = 33/546; 0.06%) (Table 3).

### Table 2. Antibiotic resistance pattern for Gram-positive bacteria.

| Antibiotics | S. aureus (n = 119) | Enterococcus spp. (n = 32) | Corynebacterium spp. (n = 62) | Streptococcus spp. (n = 277) | CoNS (n = 100) |
|-------------|---------------------|-----------------------------|-------------------------------|-------------------------------|---------------|
| AMK         | - 50 69             | - 19 13                     | - 12 50                       | + - -                        | - 25 75       |
| AMP         | - 72 47             | - 12 20                     | - 42 19                       | + - -                        | - 12 88       |
| CRO         | + - -               | + - -                       | + - -                         | + - -                        | + - -         |
| CIP         | - 66 53             | - 9 23                      | - 32 30                       | + - -                        | - 42 58       |
| CLI         | - 67 52             | - 8 24                      | - 12 50                       | - 112 165                    | - 58 42       |
| DOX         | - 74 45             | - 23 10                     | - 31 31                       | + - -                        | - 52 48       |
| ERY         | - 59 60             | - 4 28                      | - 41 21                       | - 213 64                     | - 22 78       |
| GEN         | - 84 35             | - 21 11                     | - 22 40                       | + - -                        | - 31 69       |
| IMP         | + - -               | + - -                       | + - -                         | + - -                        | + - -         |
| NIT         | - 97 22             | - 32 -                       | - 32 30                       | + - -                        | - 31 69       |
| PEN         | - 55 64             | - 32 -                       | - 30 32                       | - 51 226                     | - 42 58       |
| TZP         | - 107 12            | - 40 12                     | - 41 21                       | + - -                        | - 74 26       |
| RIF         | - 73 46             | - 24 8                      | - 51 11                       | - 200 77                     | - 61 39       |
| TCY         | - 99 20             | - 18 14                     | - 34 28                       | - 87 190                     | - 62 39       |
| SXT         | - 66 53             | - 23 10                     | - 32 30                       | - 225 52                     | - 63 37       |
| VAN         | - 109 10            | - 10 22                     | + - -                         | - 74 203                     | - 60 40       |
| BAC         | - - 117             | - 32 -                       | + - -                         | + - -                        | - 62 38       |
| CAZ         | - 107 12            | - 27 5                      | - 28 34                       | + - -                        | - 72 28       |
| SAM         | - 95 24             | - 23 9                      | - 50 12                       | + - -                        | - 58 42       |
| TEC         | - 86 33             | - 32 -                       | - 32 30                       | + - -                        | - 89 11       |
| LEV         | - 75 44             | - 21 11                     | - 25 37                       | - 112 165                    | - 18 85       |
| MUP         | - 88 31             | - 23 10                     | + - -                         | + - -                        | - 72 28       |
| MNO         | - 99 20             | - 20 12                     | - 26 36                       | + - -                        | - 59 41       |
| LNZ         | - 114 5             | - 31 1                      | - 62 -                         | - 277 -                      | - 100 -       |
| COL         | + - -               | + - -                       | + - -                         | + - -                        | + - -         |
| CCV         | - 97 22             | + - -                       | - 23 39                       | + - -                        | - 64 36       |

Ampicillin (AMP), Gentamicin (GEN), Ciprofloxacin (CIP), Vancomycin (VAN), Ceftazidime (CAZ), Nitrofurantoin (NIT), Imipenem (IMI), Penicillin (PEN), Clindamycin (CLI), Erythromycin (ERY), Doxycycline (DOX), Trimethoprim/sulfamethoxazole (SXT), Colistin (COL), Linezolid (LNZ), Mupirocin (MUP), Rifampin (RIF), Amikacin (AMK), Ceftriaxone (CRO), Ceftazidime/Clavulanic acid (CCV), Minocycline (MNO), Cefazolin (CZO), Piperacillin/Tazobactam (TZP), Tetracycline (TCY), Ampicillin/ Sulbactam (SAM), Teicoplanin (TEC), Levofloxacin, (LEV), Bacitracin (BAC), Cefotixin (FOX), Cefotaxime (CTX), Cefepime (FEP)

https://doi.org/10.1371/journal.pone.0277329.t002
Table 2 depicts the prevalence of antibiotic resistance of GPB isolates. In case of *S. aureus* isolates, the highest resistance rates belonged to amikacin (n = 69/119; 57%), followed by penicillin (n = 64/119; 53%). However, *S. aureus* had no levels resistance to cefepime and Cefotaxime.

In case of *Corynebacterium* spp and CoNS isolates, linezolid was the most efficient antimicrobials against. CoNS strains showed high-level resistance to levofloxacin (n = 88/100; 88%) and Ampicillin (n = 85/100; 85%). The percentage distribution rates of methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-resistant CoNS (MR-CoNS) were 35% (n = 42/119) and 48% (n = 48/100), respectively. *Corynebacterium* spp. were 80% and 68% resistant to amikacin and cefepime, However, *Corynebacterium* spp. had low levels of resistance to linezolid.

### Table 3. Antibiotic resistance pattern for Gram-negative bacteria.

| Antibiotics | N.gonorrhoeae (n = 33) | Klebsiella spp (n = 97) | P. aeruginosa (n = 195) | A. baumannii (n = 121) |
|-------------|------------------------|------------------------|------------------------|------------------------|
|             | U R S U S R U S R U S R | U R S U S R U S R U S R | U R S U S R U S R U S R | U R S U S R U S R U S R |
| AMK         | + - - - 56 41 - 84 111 - 21 100 |
| AMP         | + - - - 49 48 - 72 123 - 8 113 |
| CZO         | + - - - 65 32 - 74 121 - 76 45 |
| FEP         | - 23 10 - 86 11 - 130 65 - 98 23 |
| FOX         | - 12 21 - - - + - - + - - |
| CRO         | - 8 25 - 74 23 - 119 76 - 107 14 |
| CIP         | + - - - 65 32 - 119 76 - 65 56 |
| CLI         | + - - - 61 36 - 138 57 - 56 65 |
| DOX         | + - - - 54 43 - 108 87 - 76 45 |
| ERY         | + - - - 54 43 - 128 67 - 75 46 |
| GEN         | + - - - 64 33 - 108 87 - 78 43 |
| IMP         | + - - - 65 32 - 100 95 - 65 56 |
| NIT         | + - - - 62 35 - 119 76 - 98 23 |
| PEN         | + - - - 30 67 - 151 44 - 76 45 |
| TZP         | + - - - 74 23 - 150 45 - 86 35 |
| RIF         | + - - - 80 17 - 130 65 - 86 35 |
| TCY         | _ 14 19 - 64 33 - 119 76 - 45 76 |
| SXT         | + - - - 85 12 - 139 56 - 65 56 |
| CAZ         | _ 21 12 - 54 43 - 138 55 - 65 56 |
| SAM         | + - - - 52 45 - 150 45 - 76 45 |
| LEV         | + - - - 74 23 - 150 45 - 56 65 |
| MUP         | + - - - + - - - + - - + - - |
| MNO         | + - - - 63 34 - 139 56 - 56 65 |
| LNZ         | + - - - + - - - + - - + - - |
| COL         | + - - - 85 12 - 177 18 - 100 21 |
| CCV         | + - - - + 82 15 - 172 23 - 97 25 |

Abbreviations: Ampicillin (AMP), Gentamicin (GEN), Ciprofloxacin (CIP), Ceftazidime (CAZ), Nitrofurantoin (NIT), Imipenem (IMI), Penicillin (PEN), Clindamycin (CLI), Erythromycin (ERY), Doxycycline (DOX), Trimethoprim/sulfamethoxazole (SXT), Collistin (COL), Linezolid (LNZ), Mupirocin (MUP), Rifampin (RIF), Amikacin (AMK), Ceftriaxone (CRO), Ceftazidime/Clavulanic acid (CCV), Minocycline (MNO), Cefazolin (CZO), Cefepime (FEP), Piperacillin/Tazobactam (TZP), Tetracycline (TCY), Ampicillin/Sulbactam (SAM), Levofloxacin (LEV)

https://doi.org/10.1371/journal.pone.0277329.t003

### Antimicrobials resistant rates of (GPB) isolates from endotracheal tube cultures of patients

Table 2 depicts the prevalence of antibiotic resistance of GPB isolates. In case of *S. aureus* isolates, the highest resistance rates belonged to amikacin (n = 69/119; 57%), followed by penicillin (n = 64/119; 53%). However, *S. aureus* had no levels resistance to cefepime and Cefotaxime. In case of *Corynebacterium* spp and CoNS isolates, linezolid was the most efficient antimicrobials against. CoNS strains showed high-level resistance to levofloxacin (n = 88/100; 88%) and Ampicillin (n = 85/100; 85%). The percentage distribution rates of methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-resistant CoNS (MR-CoNS) were 35% (n = 42/119) and 48% (n = 48/100), respectively. *Corynebacterium* spp. were 80% and 68% resistant to amikacin and cefepime, However, *Corynebacterium* spp. had low levels of resistance to linezolid.
and clindamycin. In case of *Streptococcus* spp. isolates, the highest resistance rates belonged to cefepime (n = 69/277; 65%), followed by penicillin (n = 64/277; 94%), clindamycin (n = 64/277; 59%) and tetracycline (n = 64/277; 68%). However, *Streptococcus* spp. had the low levels of resistance to rifampin and Trimethoprim-sulfamethoxazole. Detailed information on other GPBs is listed in Table 2.

**Antimicrobials resistant rates of (GNB) isolates from endotracheal tube cultures of patients**

Among GNBs, *P. aeruginosa* isolates were 66% resistant to cefepime and 76% to colistin. However, *P. aeruginosa* showed low level of resistance to piperacillin /tazobactam and gentamycin. Colistin was the most effective antibiotic against *A. baumannii* and *Klebsiella* spp. *Klebsiella* spp isolates were resistant to ciprofloxacin in 71% of cases and amikacin in 67% of cases. Table 3 shows the incidences of resistance of each GNB to routinely used antimicrobials.

**Prevalence of MDR and XDR in GPB and GNB**

The incidence rate of MDR and XDR bacterial infection from patients’ endotracheal tubes was determined by reference and is displayed in (Table 4) Out of total of 1136 bacterial strains studied, 365 (32%) bacterial strains were MDR, 441 (38%) strains were non-MDR, and 332 (29%) strains were XDR. Amongst 593 GPB strains isolated, 220 (37%) strains were MDR, 276 (46%) were non-MDR and 161(27.8%) XDR, respectively. Out from 546 GNB isolates, 146 (26%) were MDR, 276 (50%) were non-MDR, and 171 (31%) were XDR. There was no evidence of a PDR strain. Table 4 illustrates the frequency of MDR and XDR rates of GNB and GNB.

**Biofilm formation rates of GPB**

Table 5 presents the data of biofilm formation using the MTP approach. Overall, of the 593 isolated bacteria, 429 (72%) were biofilm producers, of which, 292 (68%) produced strong biofilms, 83 (16%),292 (49%) produced moderate biofilms, 54 (12%) were weak biofilm producers and 221 (53%) were not biofilm producers. The capacity of biofilm formation in GPB are represented in Table 5.

**Biofilm formation rates of GNB**

The findings of biofilm formation using the MTP method are shown Table 5. In all, 345 (64.5%) of the 546 isolated bacteria were biofilm producers, with 178 (51%) formed strong

| Table 4. Determination of MDR, NonMDR and XDR in bacterial isolates. |
|-----------------------------------------------|
| **gram negative bacteria**                   |
| Acinetobacter spp (n = 121)                  | MDR% (77%) | NonMDR% (12%) | XDR% (0.09) |
| Klebsiella spp. (n = 197)                    | 73% (37%)  | 67% (34%)     | 57% (28%)   |
| P. aeruginosa (n = 195)                      | 43% (22%)  | 75% (38%)     | 77% (39%)   |
| N. gonorrhoeae (n = 33)                      | 10% (30%)  | 8% (24%)      | 15% (45%)   |
| Gram positive bacteria                       |
| S. aureus (n = 119)                          | 32% (26%)  | 26% (21%)     | 61% (51%)   |
| *Streptococcus* spp. (n = 277)               | 65% (23%)  | 162% (58%)    | 52% (18%)   |
| CoNS (n = 100)                               | 23% (23%)  | 44% (44%)     | 33% (33%)   |
| *Enterococcus* spp. (n = 32)                 | 13% (40%)  | 6% (18%)      | 13% (40%)   |
| Corynebacterium spp (n = 62)                 | 12% (20%)  | 38% (61%)     | 12% (19%)   |

https://doi.org/10.1371/journal.pone.0277329.t004
biofilms, 73 (21%) generated moderate biofilms, 94 (27%) created weak biofilms, and 207 (6%) not developed biofilms. Table 5 illustrates the ability of GPB for biofilm development.

### Table 5. Biofilm formation of Gram-positive bacteria and Gram negative bacteria.

| Gram negative bacteria               | Strong | Moderate | Weak | Non biofilm formation |
|--------------------------------------|--------|----------|------|-----------------------|
| *Acinetobacter* spp (*n* = 121)      | 65(0.09) | 12(0.09) | 12(0.09) | 32(0.09) |
| *Klebsiella* spp (*n* = 197)         | 52(0.09) | 34(0.09) | 43(0.09) | 68(0.09) |
| *P. aeruginosa* (*n* = 195)         | 49(0.09) | 21(0.09) | 29(0.09) | 102(0.09) |
| *N. gonorrhoeae* (*n* = 33)          | 12(0.09) | 6(0.09)  | 10(0.09) | 5(0.09)   |
| Gram positive bacteria               |        |          |      |                       |
| *S. aureus* (*n* = 119)              | 64(0.09) | 23(0.09) | 2(0.09)  | 30(0.09) |
| *Streptococcus* spp (*n* = 277)      | 144(0.09) | 32(0.09) | 13(0.09) | 88(0.09) |
| *CoNS* (*n* = 100)                   | 53(0.09) | 10(0.09) | 11(0.09) | 86(0.09) |
| *Enterococcus* spp (*n* = 32)       | 10(0.09) | 5(0.09)  | -       | 17(0.09) |
| *Corynebacterium* spp (*n* = 62)     | 21(0.09) | 13(0.09) | 28(0.09) | -         |

### Discussion

Following mechanical ventilation, VAP remains the most common problem, with a frequency rate of 3% during the first 5 days of ventilation, 2% between days 5 and 10, and 1% thereafter [19]. Identifying the resistance pattern of microorganisms, especially in every hospital, is an effective and acceptable technique for the treatment of VAP patients. In our hospital, the infections with Gram-positive (GPB) and Gram-negative (GNB) bacteria were 40% and 51%, respectively. Based on the results from the present study, VAP was greatly prevalent in ICU patients, and the majority of the GPB showed very high antibiotic resistance. Similarly, Lemmen et al. have reported GPB as the most frequent microorganisms isolated from the ET culture [20]. In our study, *Streptococcus* spp. was the most isolated GPB, and all of these microorganisms, regardless of *S. aureus* and *Enterococcus* spp., indicated 100% sensitivity to linezolid.

In ICUs, a link has been found between MRSA and poor clinical outcomes, exerting a remarkable burden on infection control practices in hospitals. Likewise, the ICU is a critical place for the extensive spread of MRSA because patients are admitted and discharged to various wards and hospitals [21]. In this research, the prevalence of MRSA and CoNS were 35% and 48%, respectively. However, in another research made in Iran, the incidence of MRSA was found to be 72% [22], which is significantly greater than the proportion reported in the current study. In India, methicillin resistance of *S. aureus* infections has been reported to be 13–47% [21]. Patients in a (particularly surgical) ICU have wounds, drains, and invasive monitoring devices that result in skin breaches, thereby raising the risk of developing infections. Furthermore, because of the conditions such as diabetes, chronic liver disease, or steroid therapy, impaired neutrophil properties may cause the susceptibility of these patients to MRSA.

Among GNB, *Acinetobacter*, showed a high prevalence and multidrug resistance. Colistin was the only antibiotic that could relatively control the growth of the bacterium. Besides, the incidence of pneumonia or other infection caused by *Acinetobacter* was observed to be high. This observation is comparable with previous investigations in the ICUs [23, 24]. One study reported a high incidence of VAP, and *Citrobacter* and *Klebsiella* spp were the most prevalent organisms. The two bacteria were extremely resistant to carbapenems, a routinely used antibiotic in the ICU, but showed great sensitivity to colistin (94%) [25]. *Acinetobacter*, *Klebsiella*, and *Pseudomonas* were also highly resistant to GNB to third-generation cephalosporins and
fluoroquinolones (> 80%). High resistance rates were recorded for aminoglycosides (> 68%) and imipenem (> 60%), whereas *Pseudomonas* resistance to piperacillin-tazobactam was lower than *Klebsiella* and *Acinetobacter* [26]. Other GNBs represented varied resistance patterns to the remaining antibiotics. Upadhyay and colleagues supported our finding and implied that *K. pneumoniae* was the main causative agent of VAP and resistant to third-generation antibiotics, cephalosporins, and penicillin. In contrast to the outcomes of both studies, the bacterium showed sensitivity to both carbapenems and polymyxin B [27]. Malik et al. have identified *K. pneumoniae* as the most prevalent organism responsible for VAP and reported > 60% sensitivity of bacteria to combination drugs, i.e. Cefeperazone-sulbactam and Piperacillin-tazobactam [28]. Nevertheless, there are significant differences in the types of prevalent microorganisms, as well as antibiotic resistance and sensitivity, amongst all of the research described above. Considering these discrepancies, it is necessary for hospitals to continuously investigate the incidence of VAP-causing agents and to detect their antibiotic susceptibility by relying on available medications. The current investigation found a considerable number of MDR, which is consistent with previous findings of a high volume of multi-drug resistance [29–31]. The alarming rates of MDR and XDR in hospitals are indications of the fact that antibiotic resistance is raising, and pathogenic bacteria circulating in hospitals are obtaining high resistance to the majority of available antibiotics. In Iran, antibiotics can readily be purchased from pharmacies and private drug vendors without any prescription [32]. The existence of high rates of MDR and XDR will certainly enhance the rate of mortality in patients [33]. In the current study, most of our bacteria isolated were able to produce biofilm though with varied capacities. In organisms producing biofilms, there are different mechanisms, e.g. the weak diffusion of the antimicrobial penetration through the biofilm extracellular matrix, the various growth rate of biofilm organisms, and so on, that are responsible for antimicrobial resistance. Therefore, the ability to form biofilms may be a useful approach to enhance survival and persistence under stressful situations, such as host invasion or antibiotic treatment [34, 35].

The present study explored that the capacity of biofilm formation has a significant correlation with antibiotic resistance (P < 0.001). In other words, the density of biofilm in resistance strains was greater than in susceptible ones. In this regard, some researchers affirmed our study and displayed that the resistant isolates, compared to susceptible ones, were stronger biofilm producers [36, 37]. Overall, evaluating and comparing biofilm formation between non-MDR and MDR/XDR reflected that most of the MDR/XDR isolates possess a considerably higher capacity for the formation of biofilms in comparison to non-MDR isolates. As the biofilm dynamics are temporal, the development of VAP within the first 2–5 days following intubation is more likely to be caused by antibiotic-sensitive bacteria, namely methicillin-sensitive *Staphylococcus aureus*, with a better prognosis, later occurring VAP (5 or more days after initiation of mechanical ventilation) involving frequently multidrug-resistant pathogen like MRSA, *P. aeruginosa* and extended-spectrum β-lactamase producing Enterobacteriaceae, with higher morbidity and mortality [9]. Gordon Sahuquillo and co-workers examined the use of systemic and inhaled antibiotics on a small sample of patients and observed that the aforesaid antibiotics had no effect on the persistence of variables and potentially infectious microorganisms in ET biofilm after VAP. This resistance denotes the need for device withdrawal to attain microbiological and clinical cures; however, selective ET alteration during mechanical ventilation is often not recommended [38]. Within hours following insertion, the ET is quickly colonized by microorganisms forming a biofilm on its surface. Using scanning electron microscopy, Yan et al. evaluated biofilms formed on the surface of ET after initiating ventilation for 2–7 days and observed that biofilms covered a high percentage (87.5%) of ETs after 7–10 days. The last day (10th day) was the breakpoint when all the ETs housed biofilms on
their surfaces. Indeed, the colonization of ET happens much earlier, though the validation of this matter is highly dependent on the methods assessed [1]. In a survey conducted by Adair and colleagues, in 70% of VAP patients, identical pathogens were found to exist in not only the ET biofilm but also in the lung, which is suggestive of the fact that the biofilm is an important and persistent source of pathogenic bacteria [39]. Future work with bigger populations may contribute to a deeper understanding of the microorganisms associated with the biofilm and their origins, as well as a clearer picture of the timing of biofilm formation and preventive treatments.

Conclusions
The results of this study show that there is a large volume of microbial contamination in VAP, which can be very worrying, as well as instant antibiotic resistance on the surface. Considering the previous ability to pay attention to the formation of biofilm, it can place the need in the prescription of antibiotics to check the formation of biofilm in the practice of the hospital. Colistin and linezolid are effective antibiotics against practically all resistant GPB and GPB isolates, but the elevated level of their innate resistance to antibacterial often results in the emergence of Gram-positive and gram negative bacteria. Hence, excessive use of these medications should be approached with extreme caution.

Acknowledgments
The present research work is extracted from research, which has been approved by Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Author Contributions
Conceptualization: Shahla Samei Fard, Reza Heydari.
Data curation: Zahra Dargahi.
Formal analysis: Fatemeh Jahangiri Mehr.
Investigation: Fariba Abbasi.
Methodology: Nazanin Ahmad Khosravi.
Project administration: Moloudsadat Motahar, Pejman Bakhtiyarinya.
Resources: Shahla Samei Fard.
Supervision: Ahmad Farajzade Sheikh.
Validation: Hossein Meghdadi.
Visualization: Reza Heydari, Melika Moradi.
Writing – original draft: Aram Asareh Zadegan Dezfuli.
Writing – review & editing: Anas Abdullah Hamad.

References
1. Diaconu O, Sirioiol I, Poloşanu LI, Grigoraş I. Endotracheal tube biofilm and its impact on the pathogenesis of ventilator-associated pneumonia (2018) J Crit Care Med 4(2):50. https://doi.org/10.2478/jccm-2018-0011 PMID: 30581995
2. Review Ventilator associated pneumonia (2012) Hunter JDBMJ. 344: e3325. https://doi.org/10.1136/bmj.e3325.
3. Chang JB, Wu H, Wang H, Ma BT, Wang RZ, Wei JJ (2018) Prevalence and antibiotic resistance of bacteria isolated from the cerebrospinal fluid of neurosurgical patients at Peking Union Medical College Hospital. Antimicrob Resist Infect Control 7(1):1–6. https://doi.org/10.1186/s13756-018-0323-3 PMID: 29568514

4. Sampedro GR, Bubeck Wardenburg J (2017) *Staphylococcus aureus* in the intensive care unit: are these golden grapes ripe for a new approach? J of infect dis 215(suppl_1): S64–70. https://doi.org/10.1093/infdis/jiw581

5. Pachori P, Gothalwal R, Gandhi P (2019) Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive care unit; a critical review. Genes & diseases. 6(2):109–19. https://doi.org/10.1016/j.gendis.2019.04.001

6. Nora D, Póvoa P (2017) Antibiotic consumption and ventilator-associated pneumonia rates, some parallelism but some discrepancies. Ann Transl Med 5(22): 450. https://doi.org/10.21037/atm.2017.09.16 PMID: 29264367

7. World Health Organization. New report calls for urgent action to avert antimicrobial resistance crisis. World Health Organization website. https://www.who.int/news-room/detail/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis. Accessed April. 2020.

8. Perkins SD, Woeltje KF, Angenent LT (2010) Endotracheal tube biofilm inoculation of oral flora and subsequent colonization of opportunistic pathogens. International journal of medical microbiology 300(7):503–11. https://doi.org/10.1016/j.ijmm.2010.02.005 PMID: 20510651

9. Gil-Perotin S, Ramirez P, Marti V, Sahuquillo JM, Gonzalez E, Calleja I, et al. (2012) Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care 16(3):1–9. https://doi.org/10.1186/cc11357 PMID: 22621676

10. Tran GM, Ho-Le TP, Ha DT, Tran-Nguyen CH, Nguyen TS, Pham TT, et al. (2017) Patterns of antimicrobial resistance in intensive care unit patients: a study in Vietnam. BMC infect dis 17(1):1–7. https://doi.org/10.1186/s12879-017-2529-z

11. Timsit JF, Bassetti M, Cremer O, Daikos G, De Waele J, Kallil A, et al. (2019) Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive care medicine 45(2):172–89. https://doi.org/10.1007/s00134-019-05520-5 PMID: 30659311

12. Kollef MH, Fraser VJ (2001) Antibiotic resistance in the intensive care unit. Ann Intern Med 134(4):296–314. https://doi.org/10.7326/0003-4819-134-4-200102200-00014 PMID: 11182841

13. Brusselaers N, Vogelaers D, Blot S (2011) The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 1(1):1–7.

14. Khoshfetrat M, Keykha A, Sedaghatka M, Farahmandrad R (2020) Determination of Antibiotic Resistance Pattern of Organisms Isolated from Endotracheal Tube Cultures of Patients Admitted to Intensive Care Unit. Archives of Anesthesia and Critical Care 18. https://doi.org/10.18502/aacc.v6i3.3996

15. Mahon CR, Lehman DC, Manuselis JG. Textbook of Diagnostic Microbiology. Amsterdam: Elsevier Health Sciences; 2014.

16. Performance standards for antimicrobial susceptibility testing: sixteenth informational supplement. Clinical and Laboratory Standards Institute; 2022.

17. Sweeney MT, Lubbers BV, Schwarz S, Watts JL. Applying definitions for multidrug resistance, extensive drug resistance and pandrug resistance to clinically significant livestock and companion animal bacterial pathogens. J Antimicrob Chemother. 2018 1; 73(6):1460–3. https://doi.org/10.1093/jac/dky043 PMID: 29481657

18. Zhang D, Xia J, Xu Y, et al (2016) Biological features of biofilm-forming ability of Acinetobacter baumannii strains derived from 121 elderly patients with hospital-acquired pneumonia. Clin Exp Med 16(1):73–80. https://doi.org/10.1007/s10238-014-0333-2 PMID: 25543268

19. Rello J, Torres A, Ricart M, Valles J, Gonzalez J, Artigas A, et al. (1994) Ventilator-associated pneumonia by *Staphylococcus aureus*. Comparison of mexitilin-resistant and mexitilin-sensitive episodes. Am J Respir Crit Care Med 150(6):1545–9. https://doi.org/10.1164/ajrccm.150.6.7952612 PMID: 7952612

20. Lemmen SW, Häfner H, Zölldann D, Stanzel S, Lütticken R (2004) Distribution of multi-resistant Gram-negative versus Gram-positive bacteria in the hospital inanimate environment. J Infect Control 56(3):191–7. https://doi.org/10.1016/j.jhinc.2003.12.004 PMID: 15003666

21. Mehta Y, Hegde A, Pande R, Zirpe KG, Gupta V, Ahdal J, et al. (2020) Mexitilin-resistant *Staphylococcus aureus* in intensive care unit setting of India: a review of clinical burden, patterns of prevalence, preventive measures, and future strategies. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine 24(1):55. https://doi.org/10.5005/jp-journals-10071-23337
22. Bijari A, Zade MH, Hatami S, Kalantar E, Sepehr MN, Kabir K, et al. (2018) High frequency of methicillin-resistant staphylococcus aureus in intensive care unit in Karaj, Iran. Arch Clin Infect Dis 13(5). https://doi.org/10.5812/archcid.61917

23. Ben-Chetrit E, Wiener-Well Y, Lesho E, Kopuit P, Broyer C, Bier L, et al. (2018) An intervention to control an ICU outbreak of carbapenem-resistant Acinetobacter baumannii: long-term impact for the ICU and hospital. Crit Care. 22(1):1–0. https://doi.org/10.1186/s13054-018-2247-y

24. Agodi A, Zarrilli R, Barchitta M, Anzaldi A, Di Popolo A, Mattaliano A, et al. (2006) Alert surveillance of intensive care unit-acquired Acinetobacter infections in a Sicilian hospital. Clin microbial infect 12(3):241–7. https://doi.org/10.1111/J.1469-0691.2005.01339.X

25. Thakuria B, Singh P, Agrawal S, Asthana V (2013) Profile of infective microorganisms causing ventilator-associated pneumonia: A clinical study from resource limited intensive care unit. J Anaesthesiol Clin Pharmacol 29(3):361. https://doi.org/10.4103/0970-9185.117111 PMID: 24106362

26. Ahsan AA, Barai L, Faruq MO, Fatema K, Ahmed F, Saha DK, et al. (2016) Antibiotic resistance pattern among bacteria causing ventilator associated pneumonia in an intensive care unit of Bangladesh. Bangladesh critical care journal 4(2):69–73.

27. Upadhyay V, Kumar A, Jayesh AK (2018) A Study of Microbial Colonization and their Antibiotic Resistance Pattern in Endotracheal Aspirate Cultures in Intensive Care Unit Patients at a Tertiary Care Hospital of Eastern UP, India. Int. J. Curr. Microbiol. App. Sci. 2018; 7(4):2298–306. https://doi.org/10.20546/ijcmas704.263

28. Malik MI, Malik M, Chaudhary A (2018) Antimicrobial susceptibility pattern of bacteria isolated from tracheal secretions in intensive care units admitted patients of Lahore General Hospital. Pak J Chest Med 24(2):72–7.

29. De Waele JJ, Boelens J, Leroux-Roels I (2020) Multidrug-resistant bacteria in ICU: fact or myth. Curr Opin Anaesthesiol 33(2):156–61. https://doi.org/10.1097/ACO.0000000000000830 PMID: 31904697

30. Kernéis S, Lucet JC (2019) Controlling the diffusion of multidrug-resistant organisms in intensive care units. InSeminars in respiratory and critical care medicine 40(04):558–568. Thieme Medical Publishers. https://doi.org/10.1055/s-0039-1696980 PMID: 31585481

31. Strich JR, Palmore TN (2017) Preventing transmission of multidrug-resistant pathogens in the intensive care unit. Infectious Disease Clinics 31(3):535–50. https://doi.org/10.1016/j.idc.2017.05.010 PMID: 28687211

32. Gashaw M, Berhane M, Bekele S, Kibru G, Teshager Yilma, et al. (2018) Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study. Antimicrob Resist Infect Control 7(1):1–8. https://doi.org/10.1186/s13756-018-0431-0 PMID: 30479751

33. Seung KJ, Keshavajee S, Rich ML (2015) Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 5(9):a017863. https://doi.org/10.1101/cshperspect.a017863 PMID: 25918181

34. Khan J, Tarar SM, Gul I, Nawaz U, Arshad M (2021) Challenges of antibiotic resistance biofilms and potential combating strategies: a review. 3 Biotech 11(4):1–5. https://doi.org/10.1007/s13205-021-02707-w PMID: 33816046

35. Singh S, Singh SK, Chowdhury I, Singh R (2017) Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents. Microbiol Res J Int 11:53. https://doi.org/10.2174/187428580171010053 PMID: 28553416

36. Qi L, Li H, Zhang C, Liang B, Li J, Wang L, et al. (2016) Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii. Frontiers in microbiology 12; 7:483. https://doi.org/10.3389/fmicb.2016.00483 PMID: 27148178

37. Cepas V, López Y, Muñoz E, Rolo D, Ardanuy C, Martí S, et al. (2019) Relationship between biofilm formation and antimicrobial resistance in gram-negative bacteria. Microb Drug Resist 25(1):72–9. https://doi.org/10.1089/mdr.2018.0027 PMID: 30142035

38. Pérez-Granda MJ, Latorre MC, Alonso B, Hortal J, Samaniego R, Bouza E, et al. (2017) Eradication of P. aeruginosa biofilm in endotracheal tubes based on lock therapy: results from an in vitro study. BMC Infect Dis 17(1):17–6. https://doi.org/10.1186/s12879-017-2856-0 PMID: 28920272

39. Cairns S, Thomas JG, Hooper SJ, Wise MP, Frost PJ, Wilson MJ, et al. (2011) Molecular analysis of microbial communities in endotracheal tube biofilms. PLoS One. 6(3):e14759. https://doi.org/10.1371/journal.pone.0014759 PMID: 21423727